Technical Analysis for NLNK - NewLink Genetics Corporation

Grade Last Price % Change Price Change
grade F 2.37 0.00% 0.00
NLNK closed unchanged on Friday, September 21, 2018, on 87 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical NLNK trend table...

Date Alert Name Type % Chg
Sep 21 Hammer Candlestick Bullish 0.00%
Sep 21 Narrow Range Bar Range Contraction 0.00%
Sep 21 Wide Bands Range Expansion 0.00%
Sep 21 Oversold Stochastic Weakness 0.00%
Sep 20 Wide Bands Range Expansion 0.00%
Sep 20 Oversold Stochastic Weakness 0.00%
Sep 19 Narrow Range Bar Range Contraction 1.28%
Sep 19 Lower Bollinger Band Walk Weakness 1.28%
Sep 19 Wide Bands Range Expansion 1.28%
Sep 19 Oversold Stochastic Weakness 1.28%

Older signals for NLNK ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

NewLink Genetics Corporation, a biopharmaceutical company, through its subsidiary, BioProtection Systems Corporation, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance cancer treatment options for patients and physicians. Its portfolio includes biologic and small-molecule immunotherapy product candidates based on proprietary HyperAcute immunotherapy technology for the treatment of various oncology indications. The company's lead product candidate, HyperAcute Pancreas cancer immunotherapy, is being studied in two Phase III clinical trials in surgically-resected pancreatic cancer patients. It is also developing HyperAcute Lung, which is being studied in a multi-center randomized, controlled Phase IIB/III clinical trials for non-small cell lung cancer; HyperAcute Melanoma that is in Phase II clinical trials for the treatment of melanoma; and a HyperAcute Renal cell cancer immunotherapy, as well as HyperAcute prostate and HyperAcute breast product candidates. In addition, the company is developing Indoximod, a small-molecule, orally bioavailable product candidate, which is being evaluated for the treatment of metastatic solid tumors in two Phase IB/II clinical trials; Provenge Indoximod that is in Phase II clinical trials for the treatment of prostate cancer; Docetaxel Indoximod, which is in Phase II clinical trials for the treatment of metastatic breast cancer; HyperAcute immunotherapy plus Indoximod that is in Phase IIB clinical trials; and NLG-919 IDO Pathway Inhibitor Candidate, which is in Phase I clinical trials for the treatment of metastatic solid tumors. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Is NLNK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 12.91
52 Week Low 2.31
Average Volume 531,612
200-Day Moving Average 5.7287
50-Day Moving Average 3.2366
20-Day Moving Average 2.7535
10-Day Moving Average 2.495
Average True Range 0.1521
ADX 52.5
+DI 8.1357
-DI 31.9649
Chandelier Exit (Long, 3 ATRs ) 2.7537
Chandelier Exit (Short, 3 ATRs ) 2.7663
Upper Bollinger Band 3.3471
Lower Bollinger Band 2.1599
Percent B (%b) 0.18
BandWidth 43.116034
MACD Line -0.2511
MACD Signal Line -0.2361
MACD Histogram -0.0151
Fundamentals Value
Market Cap 69.73 Million
Num Shares 29.4 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -1.03
Price-to-Sales 6.79
Price-to-Book 2.71
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.48
Resistance 3 (R3) 2.47 2.42 2.46
Resistance 2 (R2) 2.42 2.40 2.43 2.45
Resistance 1 (R1) 2.40 2.38 2.41 2.41 2.45
Pivot Point 2.35 2.35 2.36 2.36 2.35
Support 1 (S1) 2.33 2.33 2.34 2.34 2.29
Support 2 (S2) 2.28 2.31 2.29 2.29
Support 3 (S3) 2.26 2.28 2.28
Support 4 (S4) 2.27